Q-Line Biotech (NSE:QLINE) Short-Term Debt: ₹825 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹531.80
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Short-Term Debt?

Q-Line Biotech NSE:QLINE -1.12% 14 Short-Term Debt is ₹825 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's Short-Term Debt for the quarter that ended in Mar. 2025 was ₹825 Mil.

Q-Line Biotech's quarterly Short-Term Debt increased from Mar. 2023 (₹593 Mil) to Mar. 2024 (₹618 Mil) and increased from Mar. 2024 (₹618 Mil) to Mar. 2025 (₹825 Mil).

Q-Line Biotech's annual Short-Term Debt increased from Mar. 2023 (₹593 Mil) to Mar. 2024 (₹618 Mil) and increased from Mar. 2024 (₹618 Mil) to Mar. 2025 (₹825 Mil).

Q-Line Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Q-Line Biotech Short-Term Debt Related Terms

Q-Line Biotech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Short-Term Debt Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Short-Term Debt
593.42 618.17 825.38

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Short-Term Debt 593.42 618.17 825.38
NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹825 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Short-Term Debt of ₹825 Mil as of Mar. 2025.
Is Q-Line Biotech's Short-Term Debt too high?
Q-Line Biotech's current Short-Term Debt is ₹825 Mil. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Short-Term Debt compare to ABT and SYK?
Q-Line Biotech's Short-Term Debt of ₹825 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Q-Line Biotech's current Short-Term Debt is ₹825 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Short-Term Debt of ₹825 Mil. The current Short-Term Debt is ₹825 Mil. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Short-Term Debt is ₹825 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹531.80
Price